Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · IEX Real-Time Price · USD
1.400
-0.070 (-4.76%)
At close: Jul 19, 2024, 4:00 PM
1.390
-0.010 (-0.71%)
Pre-market: Jul 20, 2024, 9:28 AM EDT

Barinthus Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Revenue
0.330.844.70.274.826.85
Revenue Growth (YoY)
-98.89%-98.21%16580.22%-94.44%-29.57%-
Gross Profit
0.330.844.70.274.826.85
Selling, General & Admin
33.739.846.3925.1210.482.67
Research & Development
46.1944.8742.3520.3714.3929.84
Other Operating Expenses
-0.2100000
Operating Expenses
79.6884.7248.7445.4924.8732.51
Operating Income
-79.34-83.91-4.04-45.22-20.05-25.66
Interest Expense / Income
0.040.030.022.673.60.13
Other Expense / Income
-6.07-7.52-4.933-6.04-5.07
Pretax Income
-73.31-76.420.87-50.89-17.61-20.73
Income Tax
-2.6-3.08-4.47-0.030.10
Net Income
-70.72-73.355.34-50.87-17.71-20.73
Shares Outstanding (Basic)
39383726823
Shares Outstanding (Diluted)
39383826823
Shares Change
2.00%0.57%47.40%227.59%-66.32%-
EPS (Basic)
-1.84-1.910.14-1.96-2.24-883.27
EPS (Diluted)
-1.84-1.910.14-1.96-2.24-883.27
Free Cash Flow
-62.79-56.34-20.18-33.73-11.32-18.81
Free Cash Flow Per Share
-1.62-1.47-0.54-1.30-1.43-0.80
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-23755.69%-10463.09%-9.04%-16873.51%-415.81%-374.94%
Profit Margin
-21173.05%-9145.51%11.95%-18979.48%-367.27%-302.84%
Free Cash Flow Margin
-18798.50%-7024.69%-45.14%-12585.45%-234.83%-274.74%
Effective Tax Rate
---513.32%---
EBITDA
-66.23-69.646.43-47.29-13.8-20.25
EBITDA Margin
-19828.74%-8682.92%14.38%-17643.66%-286.31%-295.86%
Depreciation & Amortization
7.056.765.540.940.210.35
EBIT
-73.27-76.390.89-48.23-14.01-20.6
EBIT Margin
-21938.32%-9525.44%1.99%-17994.40%-290.62%-300.90%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).